Skip to main content
Erschienen in: Acta Neurologica Belgica 3/2017

05.06.2017 | Original Article

The effect of melatonin on gene expression of calcitonin gene-related peptide and some proinflammatory mediators in patients with pure menstrual migraine

verfasst von: Mohammad Ansari, Azam Karkhaneh, Asma Kheirollahi, Solaleh Emamgholipour, Mohammad Hessam Rafiee

Erschienen in: Acta Neurologica Belgica | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

The neuropeptide calcitonin gene-related peptide (CGRP), a potent vasoactive and a marker of trigeminal inflammation, has been considered as an important mediator in various types of migraine such as pure menstrual migraine. Earlier studies have shown that CGRP can modulate the synthesis and release of other inflammatory factor including nitric oxide (NO) and interleukin-1beta (IL-1β) from trigeminal ganglion glial cells. Exogenous melatonin protects the tissues from inflammatory damages. The goal of this study was to determine the anti-inflammatory effects of melatonin on the CGRP expression, inducible nitric oxide synthase (iNOS) activity, NO, and IL-1β release in cultured peripheral blood mononuclear cells (PBMCs) from pure menstrual migraine patients and healthy subjects. This study was performed on 12 pure menstrual migraine patients and 12 age-and sex-matched healthy subjects. PBMCs were isolated and treated with melatonin for 12 h at pharmacological dose. Gene expression was evaluated by real-time PCR. CGRP and IL-1β proteins in culture supernatant were determined by ELISA method. iNOS activity in PBMCs was determined by colorimetric assays. Total nitrite as an indicator of NO concentrations in the culture supernatants was measured using Griess method. We found that melatonin treatment significantly decreases mRNA expression of CGRP release, NO production, and iNOS activity in the patient groups. Taken together, it appears that melatonin reduces inflammation through decreasing CGRP level and iNOS activity in the patients with migraine; however, further studies are needed in this regard.
Literatur
1.
Zurück zum Zitat Headache Classification Subcommittee of the International Headache S (2004) The international classification of headache disorders. Cephalalgia: Int J Headache 24:9CrossRef Headache Classification Subcommittee of the International Headache S (2004) The international classification of headache disorders. Cephalalgia: Int J Headache 24:9CrossRef
2.
Zurück zum Zitat Ruiz de Velasco I, Gonzalez N, Etxeberria Y, Garcia-Monco JC (2003) Quality of life in migraine patients: a qualitative study. Cephalalgia 23(9):892–900PubMedCrossRef Ruiz de Velasco I, Gonzalez N, Etxeberria Y, Garcia-Monco JC (2003) Quality of life in migraine patients: a qualitative study. Cephalalgia 23(9):892–900PubMedCrossRef
3.
Zurück zum Zitat Silberstein SD, Merriam GR (1993) Sex hormones and headache. J Pain Symptom Manag 8(2):98–114CrossRef Silberstein SD, Merriam GR (1993) Sex hormones and headache. J Pain Symptom Manag 8(2):98–114CrossRef
4.
Zurück zum Zitat MacGregor EA, Hackshaw A (2004) Prevalence of migraine on each day of the natural menstrual cycle. Neurology 63(2):351–353PubMedCrossRef MacGregor EA, Hackshaw A (2004) Prevalence of migraine on each day of the natural menstrual cycle. Neurology 63(2):351–353PubMedCrossRef
5.
Zurück zum Zitat MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A (2006) Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 67(12):2154–2158PubMedCrossRef MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A (2006) Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 67(12):2154–2158PubMedCrossRef
6.
Zurück zum Zitat Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine-current understanding and treatment. N Engl J Med 346(4):257–270PubMedCrossRef Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine-current understanding and treatment. N Engl J Med 346(4):257–270PubMedCrossRef
7.
Zurück zum Zitat Edvinsson L (2003) New therapeutic target in primary headaches blocking the CGRP receptor. Expert Opin Ther Targets 7(3):377–383PubMedCrossRef Edvinsson L (2003) New therapeutic target in primary headaches blocking the CGRP receptor. Expert Opin Ther Targets 7(3):377–383PubMedCrossRef
8.
Zurück zum Zitat Goadsby PJ, Edvinsson L, Ekman R (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23(2):193–196PubMedCrossRef Goadsby PJ, Edvinsson L, Ekman R (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23(2):193–196PubMedCrossRef
9.
Zurück zum Zitat Wimalawansa SJ (1996) Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 17(5):533–585PubMedCrossRef Wimalawansa SJ (1996) Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 17(5):533–585PubMedCrossRef
10.
Zurück zum Zitat Zhang Z, Winborn CS, de Prado BM, Russo AF (2007) Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 27(10):2693–2703PubMedCrossRef Zhang Z, Winborn CS, de Prado BM, Russo AF (2007) Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 27(10):2693–2703PubMedCrossRef
11.
Zurück zum Zitat Li J, Vause CV, Durham PL (2008) Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res 1196:22–32PubMedPubMedCentralCrossRef Li J, Vause CV, Durham PL (2008) Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res 1196:22–32PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Rothwell NJ, Hopkins SJ (1995) Cytokines and the nervous system II: actions and mechanisms of action. Trends Neurosci 18(3):130–136PubMedCrossRef Rothwell NJ, Hopkins SJ (1995) Cytokines and the nervous system II: actions and mechanisms of action. Trends Neurosci 18(3):130–136PubMedCrossRef
13.
Zurück zum Zitat Peres MFP, Masruha MR, Zukerman E, Moreira-Filho CA, Cavalheiro EA (2006) Potential therapeutic use of melatonin in migraine and other headache disorders. Expert Opin Investig Drugs 15(4):367–375PubMedCrossRef Peres MFP, Masruha MR, Zukerman E, Moreira-Filho CA, Cavalheiro EA (2006) Potential therapeutic use of melatonin in migraine and other headache disorders. Expert Opin Investig Drugs 15(4):367–375PubMedCrossRef
15.
Zurück zum Zitat Brun J, Claustrat B, Saddier P, Chazot G (1995) Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 15(2):136–139PubMedCrossRef Brun J, Claustrat B, Saddier P, Chazot G (1995) Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 15(2):136–139PubMedCrossRef
16.
Zurück zum Zitat Ebadi M, Govitrapong P, Phansuwan-Pujitu P, Nelson F, Reiter RJ (1998) Pineal opioid receptors and analgesic action of melatonin. J Pineal Res 24(4):193–200PubMedCrossRef Ebadi M, Govitrapong P, Phansuwan-Pujitu P, Nelson F, Reiter RJ (1998) Pineal opioid receptors and analgesic action of melatonin. J Pineal Res 24(4):193–200PubMedCrossRef
17.
Zurück zum Zitat Gilad E, Wong HR, Zingarelli B, Virág L, O’Connor M, Salzman AL, Szab C (1998) Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NF-κB activation. FASEB J 12(9):685–693PubMed Gilad E, Wong HR, Zingarelli B, Virág L, O’Connor M, Salzman AL, Szab C (1998) Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NF-κB activation. FASEB J 12(9):685–693PubMed
18.
Zurück zum Zitat Vijayalaxmi Reiter RJ, Tan D-X, Herman TS, Thomas CR (2004) Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys 59(3):639–653PubMedCrossRef Vijayalaxmi Reiter RJ, Tan D-X, Herman TS, Thomas CR (2004) Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys 59(3):639–653PubMedCrossRef
19.
Zurück zum Zitat Gavin DP, Sharma RP (2009) Chromatin from peripheral blood mononuclear cells as biomarkers for epigenetic abnormalities in schizophrenia. Cardiovasc Psychiatry Neurol 2009:409562PubMedPubMedCentralCrossRef Gavin DP, Sharma RP (2009) Chromatin from peripheral blood mononuclear cells as biomarkers for epigenetic abnormalities in schizophrenia. Cardiovasc Psychiatry Neurol 2009:409562PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Arosio B, D’Addario C, Gussago C, Casati M, Tedone E, Ferri E, Nicolini P, Rossi PD, Maccarrone M, Mari D (2014) Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly. BioMed Res Int 2014:169203PubMedPubMedCentralCrossRef Arosio B, D’Addario C, Gussago C, Casati M, Tedone E, Ferri E, Nicolini P, Rossi PD, Maccarrone M, Mari D (2014) Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly. BioMed Res Int 2014:169203PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PML, Carathers M, Li Z-W, Beg AA, Ghosh S, Sahenk Z (2007) Interplay of IKK/NF-κB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Investig 117(4):889–901PubMedPubMedCentralCrossRef Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PML, Carathers M, Li Z-W, Beg AA, Ghosh S, Sahenk Z (2007) Interplay of IKK/NF-κB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Investig 117(4):889–901PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Avitsur R, Pollak Y, Yirmiya R (1997) Administration of lnterleukin-1 into the hypothalamic paraventricular nucleus induces febrile and behavioral effects. Neuroimmunomodulation 4(5–6):258–265PubMedCrossRef Avitsur R, Pollak Y, Yirmiya R (1997) Administration of lnterleukin-1 into the hypothalamic paraventricular nucleus induces febrile and behavioral effects. Neuroimmunomodulation 4(5–6):258–265PubMedCrossRef
24.
Zurück zum Zitat Gupta S, Mehrotra S, Villalón CM, Perusquía M, Saxena PR, MaassenVanDenBrink A (2007) Potential role of female sex hormones in the pathophysiology of migraine. Pharmacol Ther 113(2):321–340PubMedCrossRef Gupta S, Mehrotra S, Villalón CM, Perusquía M, Saxena PR, MaassenVanDenBrink A (2007) Potential role of female sex hormones in the pathophysiology of migraine. Pharmacol Ther 113(2):321–340PubMedCrossRef
25.
Zurück zum Zitat Couturier EGM, Bomhof MAM, Neven AK, Van Duijn NP (2003) Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 23(4):302–308PubMedCrossRef Couturier EGM, Bomhof MAM, Neven AK, Van Duijn NP (2003) Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 23(4):302–308PubMedCrossRef
26.
Zurück zum Zitat Waeber C, Moskowitz MA (2005) Migraine as an inflammatory disorder. Neurology 64(10 suppl 2):S9–S15PubMedCrossRef Waeber C, Moskowitz MA (2005) Migraine as an inflammatory disorder. Neurology 64(10 suppl 2):S9–S15PubMedCrossRef
27.
Zurück zum Zitat Rodríguez-Osorio X, Sobrino T, Brea D, Martínez F, Castillo J, Leira R (2012) Endothelial progenitor cells a new key for endothelial dysfunction in migraine. Neurology 79(5):474–479PubMedCrossRef Rodríguez-Osorio X, Sobrino T, Brea D, Martínez F, Castillo J, Leira R (2012) Endothelial progenitor cells a new key for endothelial dysfunction in migraine. Neurology 79(5):474–479PubMedCrossRef
28.
Zurück zum Zitat Aggarwal M, Puri V, Puri S (2012) Effects of estrogen on the serotonergic system and calcitonin gene-related peptide in trigeminal ganglia of rats. Ann Neurosci 19(4):151PubMedPubMedCentralCrossRef Aggarwal M, Puri V, Puri S (2012) Effects of estrogen on the serotonergic system and calcitonin gene-related peptide in trigeminal ganglia of rats. Ann Neurosci 19(4):151PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Durham PL (2004) CGRP-receptor antagonists–a fresh approach to migraine therapy? N Engl J Med 350(11):1073–1075PubMedCrossRef Durham PL (2004) CGRP-receptor antagonists–a fresh approach to migraine therapy? N Engl J Med 350(11):1073–1075PubMedCrossRef
30.
Zurück zum Zitat Ramadan NM (2005) Targeting therapy for migraine what to treat? Neurology 64(10 suppl 2):S4–S8PubMedCrossRef Ramadan NM (2005) Targeting therapy for migraine what to treat? Neurology 64(10 suppl 2):S4–S8PubMedCrossRef
31.
Zurück zum Zitat Regrigny O, Delagrange P, Scalbert E, Atkinson J, Lartaud-Idjouadiene I (1998) Melatonin improves cerebral circulation security margin in rats. Am J Physiol-Heart Circ Physiol 275(1):H139–H144 Regrigny O, Delagrange P, Scalbert E, Atkinson J, Lartaud-Idjouadiene I (1998) Melatonin improves cerebral circulation security margin in rats. Am J Physiol-Heart Circ Physiol 275(1):H139–H144
32.
Zurück zum Zitat Viswanathan M (2001) Melatonin inhibits calcitonin gene-related peptide-induced vasodilation and increase in cAMP in rat middle cerebral arteries. Eur J Pharmacol 415(2):247–250PubMedCrossRef Viswanathan M (2001) Melatonin inhibits calcitonin gene-related peptide-induced vasodilation and increase in cAMP in rat middle cerebral arteries. Eur J Pharmacol 415(2):247–250PubMedCrossRef
33.
Zurück zum Zitat Savaskan E, Olivieri G, Brydon L, Jockersb R, Kräuch K, Wirz-Justice A, Müller-Spahn F (2001) Cerebrovascular melatonin MT1-receptor alterations in patients with Alzheimer’s disease. Neurosci Lett 308(1):9–12PubMedCrossRef Savaskan E, Olivieri G, Brydon L, Jockersb R, Kräuch K, Wirz-Justice A, Müller-Spahn F (2001) Cerebrovascular melatonin MT1-receptor alterations in patients with Alzheimer’s disease. Neurosci Lett 308(1):9–12PubMedCrossRef
34.
Zurück zum Zitat Guglielmo R, Martinotti G, Di Giannantonio M, Janiri L (2013) A possible new option for migraine management: agomelatine. Clin Neuropharmacol 36(2):65–67PubMedCrossRef Guglielmo R, Martinotti G, Di Giannantonio M, Janiri L (2013) A possible new option for migraine management: agomelatine. Clin Neuropharmacol 36(2):65–67PubMedCrossRef
35.
Zurück zum Zitat Vogler B, Rapoport AM, Tepper SJ, Sheftell F, Bigal ME (2006) Role of melatonin in the pathophysiology of migraine. CNS Drugs 20(5):343–350PubMedCrossRef Vogler B, Rapoport AM, Tepper SJ, Sheftell F, Bigal ME (2006) Role of melatonin in the pathophysiology of migraine. CNS Drugs 20(5):343–350PubMedCrossRef
36.
Zurück zum Zitat Murialdo G, Fonzi S, Costelli P, Solinas GP, Parodi C, Marabini S, Fanciullacci M, Polleri A (1994) Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine. Cephalalgia 14(3):205–209PubMedCrossRef Murialdo G, Fonzi S, Costelli P, Solinas GP, Parodi C, Marabini S, Fanciullacci M, Polleri A (1994) Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine. Cephalalgia 14(3):205–209PubMedCrossRef
37.
Zurück zum Zitat Durham PL (2004) CGRP-receptor antagonists- a fresh approach to migraine therapy? N Engl J Med 350(11):1073–1075PubMedCrossRef Durham PL (2004) CGRP-receptor antagonists- a fresh approach to migraine therapy? N Engl J Med 350(11):1073–1075PubMedCrossRef
38.
Zurück zum Zitat Kankuri E, Asmawi MZ, Korpela R, Vapaatalo H, Moilanen E (1999) Induction of iNOS in a rat model of acute colitis. Inflammation 23(2):141–152PubMedCrossRef Kankuri E, Asmawi MZ, Korpela R, Vapaatalo H, Moilanen E (1999) Induction of iNOS in a rat model of acute colitis. Inflammation 23(2):141–152PubMedCrossRef
39.
Zurück zum Zitat Clark AK, Old EA, Malcangio M (2013) Neuropathic pain and cytokines: current perspectives. J Pain Res 6:803–814PubMedPubMedCentral Clark AK, Old EA, Malcangio M (2013) Neuropathic pain and cytokines: current perspectives. J Pain Res 6:803–814PubMedPubMedCentral
40.
Zurück zum Zitat Lopez A, Garcia JA, Escames G, Venegas C, Ortiz F, Lopez LC, Acuña-Castroviejo D (2009) Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J Pineal Res 46(2):188–198PubMedCrossRef Lopez A, Garcia JA, Escames G, Venegas C, Ortiz F, Lopez LC, Acuña-Castroviejo D (2009) Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J Pineal Res 46(2):188–198PubMedCrossRef
41.
Zurück zum Zitat Crespo E, MaclAs M, Pozo D, Escames G, MartlN M, Vives F, Guerrero JM, AcunA-Castroviejo D (1999) Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J 13(12):1537–1546PubMed Crespo E, MaclAs M, Pozo D, Escames G, MartlN M, Vives F, Guerrero JM, AcunA-Castroviejo D (1999) Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J 13(12):1537–1546PubMed
42.
Zurück zum Zitat Escames G, Lopez LC, Tapias V, Utrilla P, Reiter RJ, Hitos AB, Leon J, Rodríguez Maria I, Acuña-Castroviejo D (2006) Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. J Pineal Res 40(1):71–78PubMedCrossRef Escames G, Lopez LC, Tapias V, Utrilla P, Reiter RJ, Hitos AB, Leon J, Rodríguez Maria I, Acuña-Castroviejo D (2006) Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. J Pineal Res 40(1):71–78PubMedCrossRef
43.
Zurück zum Zitat Strecker T, Dux M, Messlinger K (2002) Increase in meningeal blood flow by nitric oxide interaction with calcitonin gene-related peptide receptor and prostaglandin synthesis inhibition. Cephalalgia 22(3):233–241PubMedCrossRef Strecker T, Dux M, Messlinger K (2002) Increase in meningeal blood flow by nitric oxide interaction with calcitonin gene-related peptide receptor and prostaglandin synthesis inhibition. Cephalalgia 22(3):233–241PubMedCrossRef
44.
Zurück zum Zitat Chen H-M, Chen J-C, Ng C-J, Chiu D-F, Chen M-F (2006) Melatonin reduces pancreatic prostaglandins production and protects against caerulein-induced pancreatitis in rats. J Pineal Res 40(1):34–39PubMedCrossRef Chen H-M, Chen J-C, Ng C-J, Chiu D-F, Chen M-F (2006) Melatonin reduces pancreatic prostaglandins production and protects against caerulein-induced pancreatitis in rats. J Pineal Res 40(1):34–39PubMedCrossRef
45.
Zurück zum Zitat Bubenik GA, Blask DE, Brown GM, Maestroni GJM, Pang SF, Reiter RJ, Viswanathan M, Zisapel N (1998) Prospects of the clinical utilization of melatonin. Neurosignals 7(4):195–219CrossRef Bubenik GA, Blask DE, Brown GM, Maestroni GJM, Pang SF, Reiter RJ, Viswanathan M, Zisapel N (1998) Prospects of the clinical utilization of melatonin. Neurosignals 7(4):195–219CrossRef
46.
Zurück zum Zitat Jung KH, Hong S-W, Zheng H-M, Lee D-H, Hong S-S (2009) Melatonin downregulates nuclear erythroid 2-related factor 2 and nuclear factor-kappaB during prevention of oxidative liver injury in a dimethylnitrosamine model. J Pineal Res 47(2):173–183PubMedCrossRef Jung KH, Hong S-W, Zheng H-M, Lee D-H, Hong S-S (2009) Melatonin downregulates nuclear erythroid 2-related factor 2 and nuclear factor-kappaB during prevention of oxidative liver injury in a dimethylnitrosamine model. J Pineal Res 47(2):173–183PubMedCrossRef
47.
Zurück zum Zitat Sulli A, Maestroni GJM, Villaggio B, Hertens E, Craviotto C, Pizzorni C, Briata M, Seriolo B, Cutolo M (2002) Melatonin serum levels in rheumatoid arthritis. Ann N Y Acad Sci 966(1):276–283PubMedCrossRef Sulli A, Maestroni GJM, Villaggio B, Hertens E, Craviotto C, Pizzorni C, Briata M, Seriolo B, Cutolo M (2002) Melatonin serum levels in rheumatoid arthritis. Ann N Y Acad Sci 966(1):276–283PubMedCrossRef
48.
Zurück zum Zitat Peres MFP (2005) Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 25(6):403–411PubMedCrossRef Peres MFP (2005) Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 25(6):403–411PubMedCrossRef
49.
Zurück zum Zitat Miano S, Parisi P, Pelliccia A, Luchetti A, Paolino MC, Villa MP (2008) Melatonin to prevent migraine or tension-type headache in children. Neurol Sci 29(4):285–287PubMedCrossRef Miano S, Parisi P, Pelliccia A, Luchetti A, Paolino MC, Villa MP (2008) Melatonin to prevent migraine or tension-type headache in children. Neurol Sci 29(4):285–287PubMedCrossRef
50.
Zurück zum Zitat Gimeno MF, Landa A, Sterin-Speziale N, Cardinali DP, Gimeno AL (1980) Melatonin blocks in vitro generation of prostaglandin by the uterus and hypothalamus. Eur J Pharmacol 62(4):309–317PubMedCrossRef Gimeno MF, Landa A, Sterin-Speziale N, Cardinali DP, Gimeno AL (1980) Melatonin blocks in vitro generation of prostaglandin by the uterus and hypothalamus. Eur J Pharmacol 62(4):309–317PubMedCrossRef
Metadaten
Titel
The effect of melatonin on gene expression of calcitonin gene-related peptide and some proinflammatory mediators in patients with pure menstrual migraine
verfasst von
Mohammad Ansari
Azam Karkhaneh
Asma Kheirollahi
Solaleh Emamgholipour
Mohammad Hessam Rafiee
Publikationsdatum
05.06.2017
Verlag
Springer International Publishing
Erschienen in
Acta Neurologica Belgica / Ausgabe 3/2017
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-017-0803-x

Weitere Artikel der Ausgabe 3/2017

Acta Neurologica Belgica 3/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.